STOCK TITAN

Entrada Therapeutics, Inc. - TRDA STOCK NEWS

Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.

Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biopharmaceutical company pioneering intracellular therapeutics through its proprietary EEV™ platform. This page provides investors and industry observers with timely updates on clinical developments, strategic partnerships, and regulatory milestones.

Access consolidated news about TRDA's innovative approach to neuromuscular diseases and other complex conditions. Track progress across their pipeline, including Phase 1/2 trials for Duchenne muscular dystrophy candidates and platform expansions into new therapeutic areas.

Key updates include:
• Clinical trial results
• Research collaborations
• Regulatory filings
• Strategic initiatives

Bookmark this page for direct access to verified TRDA announcements and analysis. Check regularly for developments in intracellular medicine advancements and their potential impact on patient care.

Rhea-AI Summary

Entrada Therapeutics (NASDAQ: TRDA) reported positive Q2 2024 financial results and clinical progress. Key highlights include:

1. Positive Phase 1 data for ENTR-601-44 in DMD, showing dose-dependent plasma and muscle concentration, and exon skipping.

2. Planning for global Phase 2 trials for ENTR-601-44 and ENTR-601-45, with regulatory filings expected in Q4 2024.

3. Completed a $100 million registered direct offering, extending cash runway into 2027.

4. Strong financial position with $470 million in cash and equivalents as of June 30, 2024.

5. Q2 collaboration revenue of $94.7 million, up from $18.2 million in Q2 2023.

6. Net income of $55.0 million for Q2 2024, compared to a net loss of $25.9 million in Q2 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.26%
Tags
-
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company, announced a $100 million registered direct offering. The purchase involves 3,367,003 shares of common stock and pre-funded warrants to purchase an equal amount of common stock. The offering price per share is $14.85, while the pre-funded warrants are priced slightly lower at $14.8499 due to a minimal exercise price of $0.0001 per warrant. The offering is led by a U.S. healthcare investor, two global mutual funds, and Janus Henderson Investors. The funds will support ongoing clinical trials, research, and other corporate needs. The transaction is expected to close around June 25, 2024, subject to customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
-
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) has reported positive preliminary data from its Phase 1 trial ENTR-601-44-101 for Duchenne Muscular Dystrophy (DMD). The drug, ENTR-601-44, was well tolerated, showing no serious adverse events. Significant plasma and muscle concentrations were observed, suggesting a clinically meaningful starting dose for Phase 2 trials. The trial included 32 healthy male volunteers, with doses ranging from 0.75 mg/kg to 6 mg/kg. The study demonstrated statistically significant exon skipping in the highest dose cohort, with plans for regulatory filings for Phase 2 trials in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
Rhea-AI Summary

Entrada Therapeutics, a clinical-stage biopharmaceutical company listed on Nasdaq as TRDA, announces its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Dipal Doshi will present in a fireside chat scheduled for June 10, 2024, at 4:00 p.m. ET in Miami, FL. The session will be webcast live on the company's website, with a replay available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
-
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company focused on developing medicines targeting intracellular areas, announced its CEO, Dipal Doshi, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will occur on May 20, 2024, at NASDAQ in New York, NY, starting at 9:30 a.m. Eastern Time. A live webcast and a 90-day replay will be accessible on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
conferences
-
Rhea-AI Summary

Entrada Therapeutics, a clinical-stage biopharmaceutical company, reported its financial results for the first quarter of 2024. The company is focused on developing new medicines targeting intracellular targets. They achieved significant milestones, including dosing for the fourth cohort of a Phase 1 trial for DMD and receiving a $75 million payment from Vertex. With $327 million in cash, the company expects its cash runway to extend through 2026. Collaboration revenue increased to $59.1 million, while R&D expenses rose to $28.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
Rhea-AI Summary
Entrada Therapeutics, Inc. (TRDA) extends cash runway through Q2 2026 with $352 million in cash, completes dosing for Phase 1 trial of ENTR-601-44 for DMD, plans regulatory applications for Phase 2 development, and reports financial results for Q4 and full year ending December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
-
Rhea-AI Summary
Entrada Therapeutics, Inc. (Nasdaq: TRDA) will participate in two investor conferences to discuss its intracellular Endosomal Escape Vehicle (EEV™)-therapeutics. CEO Dipal Doshi will join a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, and President Nathan Dowden will participate in the TD Cowen 44th Annual Health Care Conference. Webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
-
Rhea-AI Summary
Entrada Therapeutics, Inc. (Nasdaq: TRDA) promotes Nathan J. Dowden to President and Chief Operating Officer, effective January 1, 2024. With 30 years of experience in the healthcare sector, Mr. Dowden has been instrumental in guiding Entrada's growth, advancing its lead program, and establishing new headquarters in Boston. He aims to continue driving Entrada's operational growth and making a difference for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.03%
Tags
none
Rhea-AI Summary
Entrada Therapeutics, Inc. (TRDA) completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101. U.S. FDA clinical hold on IND application remains in effect. Cash runway expected through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.85%
Tags
none
Entrada Therapeutics, Inc.

Nasdaq:TRDA

TRDA Rankings

TRDA Stock Data

295.49M
30.24M
17.5%
82.12%
3.68%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON